Filter By Category
Archives
Share on -
ABEMACICLIB
Generic Name: ABEMACICLIB
ABSTRACT -
Abemaciclib is an oral CDK4/6 inhibitor used in selected hormone receptor-positive, HER2-negative breast cancer settings. By inhibiting CDK4 and CDK6, it reduces retinoblastoma-protein phosphorylation and slows cell-cycle progression from G1 to S phase.
DOSAGE –
Use the current locally approved prescribing information where a product is authorized. For investigational products, dose, route, schedule, premedication, and dose modifications must come only from the applicable clinical-trial protocol. No dose should be selected from this summary.
SIDE EFFECTS –
- Infusion- or injection-site reactions
- Headache or fatigue
- Fever or chills
- Rash or itching
- Infections or blood-count changes, depending on target
- Target-related immune or organ toxicity
ALLRGIC REACTIONS–
(These symptoms may indicate a serious allergic or infusion reaction and require medical attention.)
- Hives or a rapidly spreading rash
- Swelling of the face, lips, tongue, or throat
- Wheezing, breathing difficulty, or sudden dizziness
- Severe blistering, mucosal lesions, or anaphylaxis
DRUG INTERACTIONS -
- Strong CYP3A inhibitors may increase exposure
- Strong CYP3A inducers may reduce exposure
- Other myelosuppressive medicines can increase cytopenias
PRECAUTIONS –
- Monitor blood counts and liver function
- Treat diarrhoea promptly and maintain hydration
- Assess for thrombosis and new respiratory symptoms
- Follow pregnancy-prevention guidance
WARNINGS –
- Severe diarrhoea, neutropenia, hepatotoxicity, thrombosis, and pneumonitis can occur
- Fever with neutropenia requires urgent assessment
Share on -
. Developed by